

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANGE OF FINANCIAL YEAR END DATE

This announcement is made by Tianda Pharmaceuticals Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

CHANGE OF FINANCIAL YEAR END DATE

The board (the “Board”) of directors (the “Directors”) of the Company announces that it has resolved to change the financial year end date of the Company from 31 March to 31 December. Accordingly, the forthcoming financial year end date of the Company will be 31 December 2022 and the next audited consolidated financial statements of the Company will be for the period of nine months from 1 April 2022 to 31 December 2022.

REASONS FOR THE CHANGE

The change of the financial year end date of the Company is to align the financial year end date of the Company with that of the principal operating subsidiaries of the Company, which are statutorily required to fix their financial year end date at 31 December in the People’s Republic of China. The Board considers that the change of the financial year end date will better facilitate the preparation of the consolidated financial statements of the Group.

To the best of its knowledge and belief, the Board does not foresee any material adverse impact on the Group resulting from the change of financial year end date of the Company and there is no other significant matter that needs to be brought to the attention of the shareholders of the Company in this regard.

SUBSEQUENT FINANCIAL REPORTING PERIODS

Following the change of financial year end date of the Company from 31 March to 31 December, the Company will announce and publish its financial results with respect to the following financial periods on or before the following relevant dates:

Financial period covered	Deadline for results announcement	Deadline for dispatch of financial report
Audited final results of the Group for the nine months ending 31 December 2022	31 March 2023	30 April 2023
Unaudited interim results for the six months ending 30 June 2023	31 August 2023	30 September 2023

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 25 November 2022

As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. SHEN Bo and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.